{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:03:22Z","timestamp":1787313802066,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jpba.2025.116770","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T19:05:55Z","timestamp":1740510355000},"page":"116770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Development and validation of an LC\u2013MS\/MS method for pharmacokinetic assessment of a bispecific antibody (YBSW015) targeting SARS-CoV-2"],"prefix":"10.1016","volume":"260","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5583-405X","authenticated-orcid":false,"given":"Yuan-Yuan","family":"Chai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7311-212X","authenticated-orcid":false,"given":"Ke","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2701-7078","authenticated-orcid":false,"given":"Zhi-Jiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.116770_bib1","unstructured":"WHO Coronavirus (COVID-19) Dashboard. \u3008https:\/\/covid19.who.int\/\u3009, 2024 (Accessed 22 July 2024)."},{"issue":"1","key":"10.1016\/j.jpba.2025.116770_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/13543784.2022.2030310","article-title":"Monoclonal antibody therapies in the management of SARS-CoV-2 infection","volume":"31","author":"Miguez-Rey","year":"2022","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.jpba.2025.116770_bib3","unstructured":"E.M. Agency, EMA issues advice on use of sotrovimab (VIR-7831) for treating COVID-19, \u3008https:\/\/www.aifa.gov.it\/documents\/20142\/1289823\/2021.05.21_com_EMA_COVID-19_raccomandazioni_uso_sotrovimab_EN.pdf\u3009, 2021 (Accessed 22 July 2024)."},{"issue":"18","key":"10.1016\/j.jpba.2025.116770_bib4","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s40265-021-01626-7","article-title":"Regdanvimab: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"issue":"7853","key":"10.1016\/j.jpba.2025.116770_bib5","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","article-title":"SARS-CoV-2 evolution during treatment of chronic infection","volume":"592","author":"Kemp","year":"2021","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jpba.2025.116770_bib6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.jpba.2025.116770_bib7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.jpba.2025.116770_bib8","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.cell.2016.04.050","article-title":"Bispecific anti-HIV-1 antibodies with enhanced breadth and potency","volume":"165","author":"Bournazos","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jpba.2025.116770_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/srep19193","article-title":"Bispecific antibody affords complete post-exposure protection of mice from both ebola (Zaire) and sudan viruses","volume":"6","author":"Frei","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jpba.2025.116770_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12977-019-0493-y","article-title":"Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1","volume":"16","author":"Moshoette","year":"2019","journal-title":"Retrovirology"},{"issue":"3","key":"10.1016\/j.jpba.2025.116770_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41590-022-01138-w","article-title":"An engineered bispecific human monoclonal antibody against SARS-CoV-2","volume":"23","author":"Li","year":"2022","journal-title":"Nat. Immunol."},{"issue":"6496","key":"10.1016\/j.jpba.2025.116770_bib12","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jpba.2025.116770_bib13","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10337-015-2866-2","article-title":"Development and validation of LC\u2013MS\/MS method for the quantitation of infliximab in human serum","volume":"78","author":"Peng","year":"2015","journal-title":"Chromatographia"},{"issue":"38","key":"10.1016\/j.jpba.2025.116770_bib14","doi-asserted-by":"crossref","first-page":"12889","DOI":"10.1021\/acs.analchem.1c01613","article-title":"Liquid chromatography-multiple reaction monitoring-mass spectrometry a ssay for quantitative measurement of therapeutic antibody cocktail REG","volume":"93","author":"Zhong","year":"2021","journal-title":"Anal. Chem."},{"issue":"3","key":"10.1016\/j.jpba.2025.116770_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4798","article-title":"Technologies to improve the sensitivity of existing chromatographic me thods used for bioanalytical studies","volume":"34","author":"Chen","year":"2020","journal-title":"Biomed. Chromatogr."},{"issue":"19","key":"10.1016\/j.jpba.2025.116770_bib16","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.4155\/bio-2023-0129","article-title":"Quantitative bioanalysis of proteins by digestion and LC-MS\/MS: the us e of multiple signature peptides","volume":"15","author":"Sleumer","year":"2023","journal-title":"Bioanalysis"},{"issue":"20","key":"10.1016\/j.jpba.2025.116770_bib17","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1007\/s00216-018-1127-2","article-title":"Proteins and antibodies in serum, plasma, and whole blood\u2014size characterization using asymmetrical flow field-flow fractionation (AF4)","volume":"410","author":"Leeman","year":"2018","journal-title":"Anal. Bioanal. Chem."},{"issue":"1-2","key":"10.1016\/j.jpba.2025.116770_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jim.2013.08.009","article-title":"Bioanalytical platform comparison using a generic human IgG PK assay format","volume":"397","author":"Leary","year":"2013","journal-title":"J. Immunol. Methods"},{"issue":"16","key":"10.1016\/j.jpba.2025.116770_bib19","doi-asserted-by":"crossref","first-page":"8336","DOI":"10.1021\/ac501837t","article-title":"A novel and cost effective method of removing excess albumin from plasma\/serum samples and its impacts on LC-MS\/MS bioanalysis of therapeutic proteins","volume":"86","author":"Liu","year":"2009","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2025.116770_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jchromb.2012.06.006","article-title":"Quantification of human serum transferrin using liquid chromatography\u2013tandem mass spectrometry based targeted proteomics","volume":"902","author":"Yu","year":"2012","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"14","key":"10.1016\/j.jpba.2025.116770_bib21","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/rcm.4121","volume":"23","author":"Xia","year":"2009","journal-title":"Rapid Commun. Mass Spectrom."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525001116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525001116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:13:52Z","timestamp":1762308832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708525001116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":21,"alternative-id":["S0731708525001116"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116770","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an LC\u2013MS\/MS method for pharmacokinetic assessment of a bispecific antibody (YBSW015) targeting SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116770"}}